We use cookies necessary to giving you a better online experience. By using our website you consent to all cookies in accordance with our Privacy Policy.
Yes, I accept
Menu
Search Opener
GEC-ESTRO Urology

 

Aim of the Group:

  • Urogec group is a group of experts in Europe, who are dealing with the clinical and scientific aspects of the treatment with brachytherapy for urological tumors like prostate cancer, bladder cancer, penile cancer

  • The UROGEC group works in close collaboration with Braphyqs holding joint meetings at which common areas of work are discussed.

  • collecting scientific data about the treatment with the brachytherapy (HDR, LDR)

  • establishing multicentric studies with brachytherapy of the treatment for urological tumors (Prostate, Bladder, Penile)

 

GEC-ESTRO Urology working group report - Brachytherapy Corner

 

GEC-ESTRO Urology working group report - PDF Version

GEC-ESTRO Urology (URO-GEC) is the working group within the Groupe Européen de Curiethérapie (GEC) and the European SocieTy for Radiotherapy and Oncology (GEC-ESTRO) that focuses on brachytherapy for urological cancers, particularly prostate cancer. In common with others, the past year has presented many challenges as face-to-face meetings have been abandoned, but the virtual medium has been invaluable in maintaining contact between members. Indeed, in many instances it has enabled greater participation without the need for travel and time away from our hospitals, which for many is becoming increasingly difficult.

Against this background, we have a strong core group of 18 colleagues with most European countries represented. We have continued meetings on a regular basis, which has enabled projects to be developed and maintained.

We continue to work in close collaboration with the group that considers the brachytherapy physics quality assurance system (BRAPHYQS). Although our tradition of holding joint meetings has been put aside during this period, we maintain strong links, with attendance by BRAPHYQS group members at our meetings to provide specialist brachytherapy physics input.

Highlights of our activities and recent achievements include the following:

 

LDR BT TURP study
 

This was a prospective study to evaluate urinary function in patients undergoing low-dose-rate (LDR) brachytherapy for prostate cancer who had undergone a previous transurethral resection of the prostate (TURP). Specific planning criteria were defined to take into account the central cavity and a planning exercise was completed successfully in a multicentre setting. Subsequently, 99 patients were entered into the study with prospective measurement of urinary function post implant. The results confirm that the incidence of urinary morbidity is low and consistent with that seen in patients who have not undergone TURP. This work has been published with the important message that, with appropriate planning modifications, LDR brachytherapy after TURP can be performed safely with no greater morbidity than in patients without TURP.

 

Predictors of urinary toxicity
 

Although there are well-defined urethral constraints when planning high-dose-rate (HDR) prostate brachytherapy, their relation to urinary toxicity and in particular the dose response for development of a urethral stricture is inconsistent. There have been suggestions that urinary toxicity may be more closely related to bladder-base dosimetry than previously thought. This work reviewed the literature and evaluated a prospective series of patients to relate various dosimetry parameters to subsequent urinary toxicity. In fact there was no relation with conventional urethral constraints or bladder-base dose-volume parameters. The most predictive value was related to proximity of loaded HDR catheters and dwell times close to the urethra.

Focal prostate brachytherapy randomised controlled trial: the POWER trial

There has been considerable interest in focal treatment in recent years that spares a portion of the prostate gland from exposure to a high dose in the hope of minimising toxicity. The URO-GEC group has developed a prospective, randomised trial to evaluate this approach. The POWER study (chief investigator: Bradley Pieters, radiation oncologist, Amsterdam University Medical Centers, The Netherlands) is randomising 254 patients with biopsy-proven unilateral prostate cancer to either whole gland or hemigland brachytherapy. Funding has been obtained from the Dutch Cancer Society for data collection and analysis in Amsterdam; additional support is provided by Elekta and the Deutsche Gesellschaft für Urologie (DGU, German Society of Urology). There is a rigorous quality-assurance process with a dummy run for all centres that wish to take part; each centre must elect to deliver either HDR, 27Gy in two fractions, or LDR, 145Gy I-125 to all patients.

 

Salvage brachytherapy
 

Many centres offer salvage brachytherapy, by either LDR or HDR, for biochemical relapse in patients who have had previous external beam radiotherapy, often with a lower dose than modern protocols. There are variations in entry criteria, staging and techniques; some offer focal therapy, others whole gland irradiation. The current literature is unsatisfactory, with relatively small series of patients illustrating the range of patient selection and treatment options. To address this, and recognising that a formal trial is unrealistic, we are establishing central database led by colleagues in Gliwice, Poland, who have some of the widest experiences of salvage brachytherapy in Europe. It is hoped that the establishment of this database will enable collection of data on a large cohort of patients that can be analysed in due course to give more definitive insight into appropriate selection criteria and treatment policies.

 

ESTRO-ACROP prostate guidelines
 

The LDR brachytherapy guidelines that were drawn up by ESTRO and the European Association of Urology (EAU were published in 2000 and the HDR guidelines were last updated in 2013. Clearly there have been major changes in practice since that time, and an update of the guidelines is in preparation under the auspices of the Advisory Committee for Radiation Oncology Practice (ACROP) with ESTRO and with endorsement by the EAU. These have been the subject of prolonged discussions in our meetings over the past year. A final, agreed version is now complete and is going through the review processes with ACROP and the EAU. It is hoped that these will be published before the end of 2021.

In addition, URO-GEC provides a forum for active discussion between group members; recent examples include a review of HDR brachytherapy fractionation and proposals for future trials following the results of the focal lesion ablative microboost in prostate cancer (FLAME) study, which demonstrated the role of boost radiotherapy in prostate cancer. We are also aware that stereotactic body radiation therapy (SBRT) is becoming increasingly recognised as an effective modality and proposals for new trials that compare SBRT with brachytherapy are underway. These include possible collaboration with Canadian colleagues, who joined our recent meeting.

URO-GEC is always open to new members who are active in brachytherapy for urological cancers and who wish to contribute to our activities.

The POWER study is open to centres that have an active prostate brachytherapy programme and can commit to recruitment of patients over the next 18-24 months.

Contact: peterhoskin@nhs.net (URO-GEC) or b.r.pieters@amsterdamumc.nl (POWER)

Randomized trial of focal prostate brachytherapy

developed by UROGEC. The chief investigator is Bradley Pieters with funding from the Dutch Cancer Society. The trial design is a prospective two-arm open randomized trial comparing hemigland and whole gland prostate brachytherapy using either LDR or HDR with the primary endpoint of erectile function. The accrual target is s total of 254 patients. https://trialsearch.who.int/Trial2.aspx?TrialID=NTR727

 

LDR BT TURP study

was a prospective study to evaluate urinary function in patients undergoing LDR brachytherapy for prostate cancer who had undergone a previous TURP which has been completed and is now being prepared for publication.

 

Salvage brachytherapy

is increasingly being offered across Europe. UROGEC plan a prospective database to collect a large multicentre series of patients to provide robust data on efficacy and aid guidelines for patient selection.

 

Urinary toxicity

is relatively common and current guidelines focus on urethral constraints as a planning objective to minimize urinary toxicity. We are seeking to explore other constraints which may have more relevance to bladder function for example trigone dose to help define new tolerance doses for these regions.

LDR-Brachytherapy:

  • Ash D, Flynn A, Battermann J, de Reijke T, Lavagnini P, Blank L; ESTRO/EAU Urological Brachytherapy Group; EORTC Radiotherapy Group. ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol. 2000 Dec;57(3):315-21. https://pubmed.ncbi.nlm.nih.gov/11104892/
     
  • Salembier C, Lavagnini P, Nickers P, Mangili P, Rijnders A, Polo A, Venselaar J, Hoskin P. GEC ESTRO PROBATE Group. Tumour and target volumes in permanent prostate brachytherapy: a supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy. Radiother Oncol. 2007 Apr;83(1):3-10. https://pubmed.ncbi.nlm.nih.gov/17321620/
     
  • Henry A, Pietes BR, André Siebert F, Hoskin P; UROGEC group of GEC ESTRO with endorsement by the European Association of Urology. GEC-ESTRO ACROP prostate brachytherapy guidelines. Radiother Oncol. 2022 Feb;167:244-251. doi: 10.1016/j.radonc.2021.12.047. Epub 2022 Jan 6. PMID: 34999134. https://pubmed.ncbi.nlm.nih.gov/34999134/

 

HDR-Brachytherapy:

  • Hoskin PJ, Colombo A, Henry A, Niehoff P, Paulsen Hellebust T, Siebert FA, Kovacs G. GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: an update. Radiother Oncol. 2013 Jun;107(3):325-32. https://pubmed.ncbi.nlm.nih.gov/23773409/
     
  • Henry A, Pietes BR, André Siebert F, Hoskin P; UROGEC group of GEC ESTRO with endorsement by the European Association of Urology. GEC-ESTRO ACROP prostate brachytherapy guidelines. Radiother Oncol. 2022 Feb;167:244-251. doi: 10.1016/j.radonc.2021.12.047. Epub 2022 Jan 6. PMID: 34999134. https://pubmed.ncbi.nlm.nih.gov/34999134/

 

Prostate outlining guidelines:

  • Salembier C, Villeirs G, De Bari B, Hoskin P, Pieters BR, Van Vulpen M, Khoo V, Henry A, Bossi A, De Meerleer G, Fonteyne V. ESTRO ACROP consensus guideline on CT- and MRI-based target volume delineation for primary radiation therapy of localized prostate cancer. Radiother Oncol. 2018 Apr;127(1):49-61. https://pubmed.ncbi.nlm.nih.gov/29496279/

 

Bladder:

  • Pieters BR, van der Steen-Banasik E, Smits GA, De Brabandere M, Bossi A, Van Limbergen E . GEC-ESTRO/ACROP recommendations for performing bladder-sparing treatment with brachytherapy for muscle-invasive bladder carcinoma. Radiother Oncol. 2017 Mar;122(3):340-346. https://pubmed.ncbi.nlm.nih.gov/28049550/

 

Penile:

  • Crook JM, Haie-Meder C, Demanes DJ, Mazeron JJ, Martinez AA, Rivard MJ American Brachytherapy Society-Groupe Européen de Curiethérapie-European Society of Therapeutic Radiation Oncology (ABS-GEC-ESTRO) consensus statement for penile brachytherapy. Brachytherapy. 2013 May-Jun;12(3):191-8. https://pubmed.ncbi.nlm.nih.gov/23453681

  • Peter Hoskin, UK, chair

  • Roberto Alonzi, UK

  • Shafak Aluwini, NL

  • Alberto Bossi, F

  • Simon Buus, DK

  • Alfonso Gomez-Iturriaga, ES

  • Benjamin Guix, ES

  • Hathal Haddad, DE

  • Ann Henry, UK

  • Peter Niehoff, DE

  • Bradley Pieters, NL

  • Carl Salembier, BE

  • Maria Serra, UK

  • Andrea Slocker, ES

  • Iosif Strouthos, CY

  • Nikolaos Tselis, DE

  • Alexander Valdman, SE

  • Piotr Wojciezek, PL

Prostate cancer

  • GEC-ESTRO Handbook: https://user-swndwmf.cld.bz/20-Prostate-Cancer-GEC-ESTRO-Handbook-of-Brachytherapy

  • Hoskin PJ, Rojas AM, Bownes PJ, Lowe GJ, Ostler PJ, Bryant L. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol. 2012 May;103(2):217-22. doi: 10.1016/j.radonc.2012.01.007.

  • Salembier C, Rijnders A, Henry A, Niehoff P, André Siebert F, Hoskin P. Prospective multi-center dosimetry study of low-dose Iodine-125 prostate brachytherapy performed after transurethral resection. J Contemp Brachytherapy. 2013 Jun;5(2):63-9

  • Salembier C, Henry A, Pieters BR, Hoskin P. A history of transurethral resection of the prostate should not be a contra-indication for low-dose-rate (125)I prostate brachytherapy: results of a prospective Uro-GEC phase-II trial. J Contemp Brachytherapy. 2020 Feb;12(1):1-5.

  • Groom N, Tsang Y, Lowe G, Hoskin P Risk factors for urethral stricture following external beam radiotherapy and HDR brachytherapy for prostate cancer. Brachytherapy. 2021 Mar-Apr;20(2):302-306

  • Slevin F, Sethugavalar B, Al-Qaisieh B, Bownes P, Mason J, Smith J, Bottomley D, Henry AM. Ten-year longitudinal health-related quality of life following iodine-125 brachytherapy monotherapy for localized prostate cancer. J Contemp Brachytherapy. 2020 Dec;12(6):540-546. doi: 10.5114/jcb.2020.101686.

  • Joshua Mason, Ann Henry, Peter Bownes. Error detection thresholds for routine real time in vivo dosimetry in HDR prostate brachytherapy. Radiotherapy and Oncology 2020: 149:38-43

  • Slevin F, Rodda SL, Bownes P, Murray L, Bottomley D, Wilkinson C, Adiotomre E, Al-Qaisieh B, Dugdale E, Hulson O, Mason J, Smith J, Henry AM. A comparison of outcomes for patients with intermediate and high risk prostate cancer treated with low dose rate and high dose rate brachytherapy in combination with external beam radiotherapy. Clin Transl Radiat Oncol. 2019 Oct 14;20:1-8. doi:10.1016/j.ctro.2019.10.00

  • Van der Meer MC, Bosman PAN, Niatsetski Y, Alderliesten T, van Wieringen N, Pieters BR, Bel A. Bi-objective optimization of catheter positions for high-dose-rate prostate brachytherapy. Med Phys. 2020 Dec;47(12):6077-6086. doi: 10.1002/mp.14505.

  • Strouthos I, Tselis N, Chatzikonstantinou G, Butt S, Baltas D, Bon D, Milickovic N, Zamboglou N. High dose rate brachytherapy as monotherapy for localised prostate cancer. Radiother Oncol. 2018 Feb;126(2):270-277. doi: 10.1016/j.radonc.2017.09.038.

  • Strouthos I, Chatzikonstantinou G, Zamboglou N, Milickovic N, Papaioannou S, Bon D, Zamboglou C, Rödel C, Baltas D, Tselis N. Combined high dose rate brachytherapy and external beam radiotherapy for clinically localised prostate cancer. Radiother Oncol. 2018 Aug;128(2):301-307. doi: 10.1016/j.radonc.2018.04.031.

 

Bladder cancer 

  • GEC-ESTRO Handbook: https://user-swndwmf.cld.bz/21-Urinary-Bladder-Cancer-GEC-ESTRO-Handbook-of-Brachytherapy

  • Voskuilen CS, Bosschieter J, van Werkhoven E, Hendricksen K, Vis AN, Witteveen T, Pieters BR, Burger M, Bex A, van der Poel HG, Moonen LM, Horenblas S, Nieuwenhuijzen JA, van Rhijn BWG. Long-term survival and complications following bladder-preserving brachytherapy in patients with cT1-T2 bladder cancer. Radiother Oncol. 2019 Dec;141:130-136. doi: 10.1016/j.radonc.2019.09.026.

  • Hoskin PJ, Rojas AM, Bownes PJ, Lowe GJ, Ostler PJ, Bryant L. Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. Radiother Oncol. 2012 May;103(2):217-22. doi: 10.1016/j.radonc.2012.01.007.

  • Slevin F, Sethugavalar B, Al-Qaisieh B, Bownes P, Mason J, Smith J, Bottomley D, Henry AM. Ten-year longitudinal health-related quality of life following iodine-125 brachytherapy monotherapy for localized prostate cancer. J Contemp Brachytherapy. 2020 Dec;12(6):540-546. doi: 10.5114/jcb.2020.101686.

  • Joshua Mason, Ann Henry, Peter Bownes. Error detection thresholds for routine real time in vivo dosimetry in HDR prostate brachytherapy. Radiotherapy and Oncology 2020: 149:38-43

  • Slevin F, Rodda SL, Bownes P, Murray L, Bottomley D, Wilkinson C, Adiotomre E, Al-Qaisieh B, Dugdale E, Hulson O, Mason J, Smith J, Henry AM. A comparison of outcomes for patients with intermediate and high risk prostate cancer treated with low dose rate and high dose rate brachytherapy in combination with external beam radiotherapy. Clin Transl Radiat Oncol. 2019 Oct 14;20:1-8. doi:10.1016/j.ctro.2019.10.00.

  • Strouthos I, Tselis N, Ferentinos K, Karagiannis E, Milickovic N, Chatzikonstantinou G, Feder O, Zamboglou N. Intraluminal High-Dose-Rate Brachytherapy-An Alternative Organ-Preserving Approach for Primary Male Urothelial Carcinoma With Panurethral Involvement. Pract Radiat Oncol. 2020 Jan-Feb;10(1):e53-e56. doi: 10.1016/j.prro.2019.08.013.

 

Penile cancer

 

 

 

GEC-ESTRO Urology is supported by ESTRO and receives sponsorship from industry for its meetings.
The following companies support the GEC-ESTRO Urology working group regularly:

EZBebig-Logo-(002).jpg

Elekta_CMYK_positive_logo-(1)-(002).jpg

Varian_end_lg_rgb_blk_pos.jpg